News Releases

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment
November 15, 2021
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study
September 21, 2021
Zenith Epigenetics Announces a Publication in the Journal of Cancer Gene Therapy with Compelling Data for the Treatment of ER-Positive Breast Cancer Patients
August 17, 2021
Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer
June 24, 2021
Zenith Epigenetics Announces Clinical Collaboration with Astellas
April 22, 2021
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
March 15, 2021

About

Science & Epigenetics

Programs

Newsroom

Contact

© 2021 zenithepigenetics | Legal | Privacy

Bookmark and Share